Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Innovative Combination Immunotherapy for Metastatic Triple Negative Breast Cancer (TNBC): A Multicenter, Multi-Arm Translational Breast Cancer Research Consortium Study

NCT03971409 is registered in ClinicalTrials.gov with Laura Huppert, MD, BA as lead sponsor.

NCT NCT03971409
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03971409 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Innovative Combination Immunotherapy for Metastatic Triple Negative Breast Cancer (TNBC): A Multicenter, Multi-Arm Translational Breast Cancer Research Consortium Study
Lead sponsor
Laura Huppert, MD, BA
Phase
Phase 2
Overall status
Active, not recruiting
Start date
July 8, 2019
Completion date
January 31, 2027
Enrollment
145 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

invasive breast carcinoma, recurrent breast carcinoma, stage iii breast cancer, stage iiia breast cancer, stage iiib breast cancer, stage iiic breast cancer, stage iv breast cancer, triple-negative breast carcinoma, unresectable breast carcinoma